中华全科医师杂志
中華全科醫師雜誌
중화전과의사잡지
CHINESE JOURNAL OF GENERAL PRACTITIONERS
2013年
4期
298-299
,共2页
癌,非小细胞肺%药物疗法,联合
癌,非小細胞肺%藥物療法,聯閤
암,비소세포폐%약물요법,연합
Carcinoma,non-small cell lung%Drug therapy,combination
观察重组人血管内皮抑制素联合培美曲塞和顺铂治疗晚期非小细胞肺癌的临床疗效和不良反应.将2008年6月至2010年6月我院肿瘤科收治的79例晚期非小细胞肺癌患者分为对照组(40例)和试验组(39例),均给予培美曲塞联合顺铂治疗,试验组在此基础上加用重组人血管内皮抑制素.试验组总有效率47.5％ (19/40),明显高于对照组的25.6％ (10/39)；临床获益率试验组(33/40,82.5％)高于对照组(23/39,59.0％),组间差异有统计学意义(P＜0.05).不良反应主要为骨髓抑制和消化系统反应,组间差异无统计学意义(P＞0.05).
觀察重組人血管內皮抑製素聯閤培美麯塞和順鉑治療晚期非小細胞肺癌的臨床療效和不良反應.將2008年6月至2010年6月我院腫瘤科收治的79例晚期非小細胞肺癌患者分為對照組(40例)和試驗組(39例),均給予培美麯塞聯閤順鉑治療,試驗組在此基礎上加用重組人血管內皮抑製素.試驗組總有效率47.5％ (19/40),明顯高于對照組的25.6％ (10/39)；臨床穫益率試驗組(33/40,82.5％)高于對照組(23/39,59.0％),組間差異有統計學意義(P＜0.05).不良反應主要為骨髓抑製和消化繫統反應,組間差異無統計學意義(P＞0.05).
관찰중조인혈관내피억제소연합배미곡새화순박치료만기비소세포폐암적림상료효화불량반응.장2008년6월지2010년6월아원종류과수치적79례만기비소세포폐암환자분위대조조(40례)화시험조(39례),균급여배미곡새연합순박치료,시험조재차기출상가용중조인혈관내피억제소.시험조총유효솔47.5％ (19/40),명현고우대조조적25.6％ (10/39)；림상획익솔시험조(33/40,82.5％)고우대조조(23/39,59.0％),조간차이유통계학의의(P＜0.05).불량반응주요위골수억제화소화계통반응,조간차이무통계학의의(P＞0.05).
To explore the efficacy and safety of human recombinant endostatin (rh-endostatin) plus pemetrexed and cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC).A total of 79 patients with advanced NSCLC were randomly divided into control group (n =39,pemetrexed plus cisplatin) and study group (n =40,rh-endostatin plus pemetrexed and cisplatin).The short-term relative risks of the test group (19/40,47.5％) was significantly higher than that in the control group (10/39,25.6％).And the clinical benefit rate the test group (33/40,82.5％) was higher than that of the control group (23/39,59.0％,P ＜ 0.05).The predominant adverse effects were bone marrow suppression and digestive reactions.And the incidence rate was not significantly different between two groups.
